Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients

Moderna and Merck will jointly develop and sell a cancer vaccine that is personalized for individual patients, the companies announced Wednesday.

Read the entire article here on CNBC.

Recent News & Updates